Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion.
Selective dopamine depletion within the medial prefrontal cortex in rats is known to enhance dopamine and norepinephrine levels in the nucleus accumbens and to induce characteristic behavioral disturbances. The present study was designed to determine levels of adrenaline, apart from dopamine and norepinephrine, and metabolites in the nucleus accumbens after prefrontocortical dopamine depletion. Prefrontocortical dopamine depletion was carried out by injecting 6-hydroxydopamine, and it was validated through: the emergence of behavioral disturbances such as amphetamine-induced stereotypies, spontaneous motor hyperactivity, and enhanced "anxiety-like" responses and through postmortem quantification of catecholamine levels by using high-performance liquid chromatography. The findings indicated that lesioned rats exhibited more oral stereotypies after amphetamine, were hyperlocomotive, and showed more pronounced anxiety-like behaviors than controls. Following prefrontocortical dopamine depletion, postmortem concentrations of dopamine and norepinephrine, along with the metabolites 3,4-dihydroxyphenylacetic acid and vanillylmandelic acid, were reliably enhanced in the nucleus accumbens as expected, and dopamine turnover was decreased. Furthermore the nucleus accumbens contained higher levels of adrenaline and its transmethylated metabolite metanephrine. To sum up, prefrontocortical dopamine depletion induces motor and emotional disturbances in rats and alters the neurochemical profile of the nucleus accumbens, not only inducing dopaminergic and noradrenergic hyperactivity but also leading to adrenaline and metanephrine excess.
Espejo
E F
EF
Departamento de Fisiologia Medica y Biofisica, Facultad de Medicina, Universidad de Sevilla, E-41009 Seville, Spain. efespejo@cica.es
Miñano
J
J
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis / Q000378:metabolism; D000818:Animals; D001007:Anxiety / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D003624:Darkness; D004298:Dopamine / Q000032:analysis / Q000172:deficiency / Q000378:metabolism*; D004837:Epinephrine / Q000032:analysis / Q000378:metabolism*; D008027:Light; D008297:Male; D008676:Metanephrine / Q000032:analysis / Q000378:metabolism*; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D009714:Nucleus Accumbens / Q000737:chemistry / Q000378:metabolism*; D016627:Oxidopamine / Q000008:administration & dosage; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013037:Spatial Behavior / Q000187:drug effects; D019956:Stereotypic Movement Disorder / Q000139:chemically induced / Q000175:diagnosis; D014642:Vanilmandelic Acid / Q000032:analysis / Q000378:metabolism
D015102:3,4-Dihydroxyphenylacetic Acid; D008676:Metanephrine; D014642:Vanilmandelic Acid; D016627:Oxidopamine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine